↓ Skip to main content

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment

Overview of attention for article published in Breast Cancer Research, August 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
8 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment
Published in
Breast Cancer Research, August 2016
DOI 10.1186/s13058-016-0744-y
Pubmed ID
Authors

Marie-Claude Bourgeois-Daigneault, Lauren Elizabeth St-Germain, Dominic Guy Roy, Adrian Pelin, Amelia Sadie Aitken, Rozanne Arulanandam, Theresa Falls, Vanessa Garcia, Jean-Simon Diallo, John Cameron Bell

Abstract

Breast cancer is the most common malignant disease amongst Western women. The lack of treatment options for patients with chemotherapy-resistant or recurrent cancers is pushing the field toward the rapid development of novel therapies. The use of oncolytic viruses is a promising approach for the treatment of disseminated diseases like breast cancer, with the first candidate recently approved by the Food and Drug Administration for use in patients. In this report, we demonstrate the compatibility of oncolytic virotherapy and chemotherapy using various murine breast cancer models. This one-two punch has been explored in the past by several groups with different viruses and drugs and was shown to be a successful approach. Our strategy is to combine Paclitaxel, one of the most common drugs used to treat patients with breast cancer, and the oncolytic Rhabdovirus Maraba-MG1, a clinical trial candidate in a study currently recruiting patients with late-stage metastatic cancer. We used the EMT6, 4 T1 and E0771 murine breast cancer models to evaluate in vitro and in vivo the effects of co-treatment with MG1 and Paclitaxel. Treatment-induced cytotoxicity was assessed and plaque assays, flow cytometry, microscopy and immunocytochemistry analysis were performed to quantify virus production and transgene expression. Orthotopically implanted tumors were measured during and after treatment to evaluate efficacy and Kaplan-Meier survival curves were generated. Our data demonstrate not only the compatibility of the treatments, but also their synergistic cytopathic activity. With Paclitaxel, EMT6 and 4 T1 tumors demonstrated increased virus production both in vitro and in vivo. Our results also show that Paclitaxel does not impair the safety profile of the virus treatment. Importantly, when combined, MG1 and the drug controlled tumor growth and prolonged survival. The combination of MG1 and Paclitaxel improved efficacy in all of the breast cancer models we tested and thus is a promising alternative approach for the treatment of patients with refractory breast cancer. Our strategy has potential for rapid translation to the clinic, given the current clinical status of both agents.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 80 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 18 23%
Researcher 15 19%
Student > Master 9 11%
Student > Doctoral Student 7 9%
Student > Ph. D. Student 6 8%
Other 9 11%
Unknown 16 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 29 36%
Medicine and Dentistry 10 13%
Pharmacology, Toxicology and Pharmaceutical Science 7 9%
Immunology and Microbiology 7 9%
Agricultural and Biological Sciences 3 4%
Other 7 9%
Unknown 17 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2017.
All research outputs
#3,859,423
of 16,032,631 outputs
Outputs from Breast Cancer Research
#555
of 1,660 outputs
Outputs of similar age
#68,186
of 267,723 outputs
Outputs of similar age from Breast Cancer Research
#2
of 5 outputs
Altmetric has tracked 16,032,631 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,660 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,723 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.